Prevision Medicine has raised $5.4m in seed funding. The company is developing tests that study how a patient's living cancer cells respond to treatments.
Evertrace spotted Berend Snijder, scientific co-founder of Prevision Medicine, 514 days before the funding announcement.
Before the round
| Evertrace detected the signal | 28 April 2025 |
|---|---|
| Funding announced | 24 September 2026 |
| Time between the two | 514 days |
On 28 April 2025, Evertrace spotted the first signal of company formation for scientific co-founder Berend Snijder. The signal showed the company taking shape 514 days before its funding announcement.
What they’re building
Prevision Medicine tests living cancer cells against potential treatments to provide additional evidence for clinicians. Its approach is designed to support treatment decisions in blood cancers and solid tumors.
Scientific co-founder Berend Snijder brings research experience in precision medicine. The company's focus is making functional testing useful alongside the other information physicians use.
The round
Prevision Medicine raised $5.4 million in seed funding led by ACE Ventures, with participation from GoHub Ventures, SICTIC and angels. The funding supports commercialization, regulatory work, reimbursement coverage and expansion across Europe.
Find your next investment before the round. Explore Evertrace →
The founder detection engine for VCs
AI-powered founder detection with unmatched coverage.
Book a demo